Qiagen Management

Management criteria checks 4/4

Qiagen's CEO is Thierry Bernard, appointed in Oct 2019, has a tenure of 4.5 years. total yearly compensation is $1.99M, comprised of 49.1% salary and 50.9% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $9.20M. The average tenure of the management team and the board of directors is 6.3 years and 9.8 years respectively.

Key information

Thierry Bernard

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage49.1%
CEO tenure4.5yrs
CEO ownership0.1%
Management average tenure6.3yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Qiagen Fails To Justify Inclusion In Long-Biased, Balanced Macro Portfolio

Jul 15

Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Jun 29
Is Qiagen N.V. (NYSE:QGEN) Trading At A 36% Discount?

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

May 26
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) A Risky Investment?

Apr 29
Is Qiagen (NYSE:QGEN) A Risky Investment?

Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

Mar 30
Are Investors Undervaluing QIAGEN N.V. (NYSE:QGEN) By 31%?

CEO Compensation Analysis

How has Thierry Bernard's remuneration changed compared to Qiagen's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$979k

US$341m

Sep 30 2023n/an/a

US$485m

Jun 30 2023n/an/a

US$490m

Mar 31 2023n/an/a

US$505m

Dec 31 2022US$10mUS$950k

US$423m

Sep 30 2022n/an/a

US$488m

Jun 30 2022n/an/a

US$539m

Mar 31 2022n/an/a

US$563m

Dec 31 2021US$2mUS$900k

US$513m

Sep 30 2021n/an/a

US$311m

Jun 30 2021n/an/a

US$480m

Mar 31 2021n/an/a

US$449m

Dec 31 2020US$2mUS$900k

US$359m

Sep 30 2020n/an/a

US$191m

Jun 30 2020n/an/a

US$14m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$650k

-US$41m

Compensation vs Market: Thierry's total compensation ($USD1.99M) is below average for companies of similar size in the US market ($USD8.45M).

Compensation vs Earnings: Thierry's compensation has been consistent with company performance over the past year.


CEO

Thierry Bernard (58 yo)

4.5yrs

Tenure

US$1,991,874

Compensation

Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board since 2021 and had been its Interim Chief Executive Officer since Octo...


Leadership Team

NamePositionTenureCompensationOwnership
Thierry Bernard
CEO, MD & Member of Management Board4.5yrsUS$1.99m0.11%
$ 9.3m
Roland Sackers
CFO, MD & Member of Management Board20.3yrsUS$1.07m0.16%
$ 13.9m
Antonio Santos
Senior VP & Head of Global Operations2yrsno datano data
John Gilardi
Vice President of Corporate Communications & Investor Relations13.5yrsno datano data
Stephany Foster
Senior VP & Head of Human Resources4.5yrsno datano data
Thomas Schweins
Senior Vice President of Life Science Business Area6.3yrsno datano data
Thomas Theuringer
Senior Director & Head of External Communicationsno datano datano data
Jean-Pascal Viola
Senior VP & Head of Molecular Diagnostics Business Area8.9yrsno datano data
Jonathan Sheldon
Senior Vice President of Qiagen Digital Insights Business Area6.3yrsno datano data

6.3yrs

Average Tenure

52.5yo

Average Age

Experienced Management: QGEN's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Metin Colpan
Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board20.3yrsUS$86.50k0.19%
$ 16.4m
Elizabeth Tallett
Independent Member of the Supervisory Board12.8yrsUS$101.50k0.022%
$ 1.9m
Eva Pisa
Independent Member of the Supervisory Board1.8yrsUS$68.50kno data
Lawrence Rosen
Independent Chairman of Supervisory Board10.8yrsUS$188.50k0.0067%
$ 588.9k
Toralf Haag
Independent Member of the Supervisory Board3.3yrsUS$82.50k0.0012%
$ 104.0k
Elaine Mardis
Independent Member of the Supervisory Board9.8yrsUS$79.50k0.0019%
$ 161.6k
Rick Bright
Member of Scientific Advisory Boardno datano datano data
Peter Kaspar
Member of the Scientific Advisory Boardno datano datano data
Ross Levine
Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board8.3yrsUS$68.50k0.0076%
$ 660.5k
Patrice Nordmann
Member of the Scientific Advisory Boardno datano datano data
Neville Sanjana
Member of the Scientific Advisory Boardno datano datano data
Sarah Polonius-Teichmann
Member of the Scientific Advisory Boardno datano datano data

9.8yrs

Average Tenure

63yo

Average Age

Experienced Board: QGEN's board of directors are considered experienced (9.8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.